{"id":1017603,"date":"2026-11-05T10:42:27","date_gmt":"2026-11-05T15:42:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/collegium-reports-third-quarter-2026-financial-results-reaffirms-2026-guidance\/"},"modified":"2026-11-05T10:42:27","modified_gmt":"2026-11-05T15:42:27","slug":"collegium-reports-third-quarter-2026-financial-results-reaffirms-2026-guidance","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/collegium-reports-third-quarter-2026-financial-results-reaffirms-2026-guidance\/","title":{"rendered":"Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance"},"content":{"rendered":"
\n

\n \u2013 Generated Record Quarterly Net Revenues of $216.3 Million, Up 3% Year-over-Year \u2013<\/em>\n <\/p>\n

\n \u2013 Generated Record JORNAY PM<\/em>
\n
\n \u00ae<\/em>
\n <\/sup>
\n Quarterly Net Revenue of $51.9 Million, Up 24% Year-over-Year \u2013<\/em>\n <\/p>\n

\n \u2013 Generated AZSTARYS<\/em>
\n
\n \u00ae<\/em>
\n <\/sup>
\n Quarterly Net Revenue of $26.5 Million in First Full Quarter of Sales Under Collegium Ownership \u2013<\/em>\n <\/p>\n

\n \u2013 Generated Quarterly Pain Portfolio Net Revenues of $138.0 Million \u2013<\/em>\n <\/p>\n

\n \u2013 Announced $50 Million Accelerated Share Repurchase in Q3\u201926 \u2013<\/em>\n <\/p>\n

\n \u2013 Conference Call Scheduled for Today at 8:00 a.m. ET \u2013<\/em>\n <\/p>\n

STOUGHTON, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today reported its financial results for the quarter ended September 30, 2026, and provided a business update.<\/p>\n

\u201cWe continued to see strong demand across our ADHD portfolio, supported by expanded commercial efforts heading into the back-to-school season. JORNAY PM reached record revenues, prescriptions and prescriber adoption, with quarterly net revenue growing 24% year-over-year,\u201d said Vikram Karnani, President and Chief Executive Officer. \u201cAdditionally, in the first full quarter of Collegium\u2019s ownership of AZSTARYS, revenues exceeded $26.5 million supported by nearly 2% prescription growth year-over-year. This represents a meaningful improvement from AZSTARYS\u2019 annual prescription decline in 2025, prior to its acquisition by Collegium. These results demonstrate our ability to rapidly integrate differentiated medicines and execute targeted commercial investments to drive growth. Our pain portfolio also continues to provide a strong financial foundation as we expand our ADHD business and pursue additional opportunities to further grow and diversify Collegium.\u201d<\/p>\n

\u201cWe generated a record $216.3 million in quarterly net revenue and $121.6 million in adjusted EBITDA, with our ADHD franchise now contributing more than 36% of total revenue,\u201d said Colleen Tupper, Chief Financial Officer. \u201cWe are reaffirming our full-year 2026 financial guidance and remain committed to deploying capital in a disciplined manner, including executing on business development, paying down debt, and opportunistically returning capital to shareholders to create long-term value. Consistent with our strong cash-generation profile and capital allocation strategy, we expect to complete the previously announced $50 million accelerated share repurchase program before the end of the year, underscoring our confidence in the company\u2019s long-term growth prospects.\u201d<\/p>\n

\n ADHD Business Highlights<\/strong>\n <\/p>\n